QNCX (Quince Therapeutics) EBIT per Share : $-0.84 (TTM As of Dec. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Quince Therapeutics EBIT per Share?

Quince Therapeutics's EBIT per Share for the three months ended in Dec. 2024 was $-0.23. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2024 was $-0.84.

During the past 3 years, the average EBIT per Share Growth Rate was 35.00% per year. During the past 5 years, the average EBIT per Share Growth Rate was 23.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Quince Therapeutics's EBIT per Share or its related term are showing as below:

QNCX' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -77.8 Med: 9.4 Max: 35.4
Current: 35

During the past 8 years, the highest 3-Year average EBIT per Share Growth Rate of Quince Therapeutics was 35.40% per year. The lowest was -77.80% per year. And the median was 9.40% per year.

QNCX's 3-Year EBIT Growth Rate is ranked better than
80.49% of 1235 companies
in the Biotechnology industry
Industry Median: 7.9 vs QNCX: 35.00

Quince Therapeutics's EBIT for the three months ended in Dec. 2024 was $-10.11 Mil.

Quince Therapeutics EBIT per Share Historical Data

The historical data trend for Quince Therapeutics's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Quince Therapeutics EBIT per Share Chart

Quince Therapeutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

EBIT per Share

Get a 7-Day Free Trial

-2.70

-3.04

-1.53

-0.73

-0.84

Quince Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
EBIT per Share	Get a 7-Day Free Trial															-0.20	-0.20	-0.21	-0.20	-0.23

Quince Therapeutics EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Quince Therapeutics's EBIT per Share for the fiscal year that ended in Dec. 2024 is calculated as

	EBIT per Share		(A: Dec. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-36.17	/	43.262
=	-0.84

Quince Therapeutics's EBIT per Share for the quarter that ended in Dec. 2024 is calculated as

	EBIT per Share		(Q: Dec. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-10.109	/	43.777
=	-0.23

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.84

Quince Therapeutics (NAS:QNCX) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Quince Therapeutics EBIT per Share Related Terms

Thank you for viewing the detailed overview of Quince Therapeutics's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Quince Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Quince Therapeutics Inc (NAS:QNCX) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

611 Gateway Boulevard, Suite 273, South San Francisco, CA, USA, 94080

Website

https://www.quincetx.com

Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.

Executives

Dirk Thye	director, officer: Chief Executive Officer	6310 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Brendan Hannah	officer: Chief Business Officer	269 EAST GRAND AVE, SOUTH SAN FRANCISCO CA 94080
Charles S. Ryan	officer: President	C/O APPLIED DNA SCIENCES, INC., 50 HEALTH SCIENCES DRIVE, STONY BROOK NY 11790
David Lamond	director	C/O CORTEXYME, INC., 269 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Guenter Janhofer	officer: Chief Scientific Officer	601 GATEWAY BOULEVARD, SUITE 1250, SOUTH SAN FRANCISCO CA 94080
Luca Benatti	director	C/O INTERCEPT PHARMACEUTICALS, INC., 450 WEST 15TH STREET, SUITE 505, NEW YORK NY 10011
Margaret Mcloughlin	director	C/O CORTEXYME, INC., 269 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Ted Monohon	officer: Chief Accounting Officer	C/O FANTEX, INC., 330 TOWNSEND ST., SUITE 234, SAN FRANCISCO CA 94107
June Bray	director	C/O BIOXCEL THERAPEUTICS, INC., 555 LONG WHARF DRIVE, NEW HAVEN CT 06511
Caryn Gordon Mcdowell	officer: Chief Legal & Adm. Officer	280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Philip S Low	director	3000 KENT AVE STE A1-100, WEST LAFAYETTE IN 47906
Karen L. Smith	officer: Chief Medical Officer	C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Marwan Sabbagh	director	C/O CORTEXYME, INC., 269 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Stephen S. Dominy	director, officer: Chief Scientific Officer	C/O CORTEXYME, INC., 269 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94105
Christopher P. Lowe	officer: Chief Financial Officer	2511 N LOOP 1604,, SUITE 204, SAN ANTONIO TX 78258